Abstract:Dengue virus (DENV) is the most common vector-borne viral disease, with nearly 400 million worldwide infections each year concentrated in the tropical and subtropical regions of the world. Severe dengue complications are often associated with a secondary heterotypic infection of one of the four circulating serotypes. In this scenario, humoral immune responses targeting cross-reactive, poorly neutralizing epitopes can lead to increased infectivity of susceptible cells via antibody-dependent enhancement (ADE). In this way, antibodies produced in response to infection or vaccination are capable of contributing to enhanced disease in subsequent infections. Currently, there are no available therapeutics to combat DENV disease, and there is an urgent need for a safe and efficacious vaccine. Here, we developed a nucleotide-modified mRNA vaccine encoding the membrane and envelope structural proteins from DENV serotype 1 encapsulated in lipid nanoparticles (prM/E mRNA-LNP). Vaccination of mice elicited robust antiviral immune responses comparable to viral infection, with high levels of neutralizing antibody titers and antiviral CD4 + and CD8 + T cells. Immunocompromised AG129 mice vaccinated with the prM/E mRNA-LNP vaccine were protected from a lethal DENV challenge. Vaccination with either a wild-type vaccine or a vaccine with mutations in the immunodominant fusion loop epitope elicited equivalent humoral and cell-mediated immune responses. Neutralizing antibodies elicited by the vaccine were sufficient to protect against a lethal challenge. Both vaccine constructs demonstrated serotype-specific immunity with minimal serum cross-reactivity and reduced ADE in comparison to a live DENV1 viral infection. IMPORTANCE With 400 million worldwide infections each year, dengue is the most common vector-borne viral disease. Forty percent of the world's population is at risk, with dengue experiencing consistent geographic spread over the years. With no therapeutics available and vaccines performing suboptimally, the need for an effective dengue vaccine is urgent. Here, we develop and characterize a novel mRNA vaccine encoding the dengue serotype 1 envelope and premembrane structural proteins that is delivered via a lipid nanoparticle. Our DENV1 prM/E mRNA-LNP vaccine induces neutralizing antibody and cellular immune responses in immunocompetent mice and protects an immunocompromised mouse from a lethal DENV challenge. Existing antibodies against dengue can enhance subsequent infections via antibody-dependent enhancement (ADE). Importantly our vaccine induced only serotype-specific immune responses and did not induce ADE.

A Dose-Response Study in Mice of a Tetravalent Recombinant Dengue Envelope Domain III Protein Secreted from Insect Cells.

Tetravalent Recombinant Dengue Virus-Like Particles As Potential Vaccine Candidates: Immunological Properties.

Induction of Neutralizing Antibodies Against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine.

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice

Preparation of Antibodies against Soluble Recombinant Dengue E Proteins Fused with Glutathione's Transferase

Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice

A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses

A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement

Novel AAV-based Genetic Vaccines Encoding Truncated Dengue Virus Envelope Proteins Elicit Humoral Immune Responses in Mice

Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate

Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach

Preparation and Characterization of Monoclonal Antibody Against M Protein of Dengue Virus Serotype 2

Induction of Multiple Cytotoxic T Lymphocyte Responses in Mice by a Multiepitope DNA Vaccine Against Dengue Virus Serotype 1.

Multivalent administration of dengue E dimers on liposomes elicits type-specific neutralizing responses without immune interference

Generation of dengue 3 envelope domain III using tobacco mosaic virus-based vector system and its immunological response mouse model by generating anti-dengue virus antibodies

Domain III of the envelope protein as a dengue vaccine target

Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice

Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody

The Innate Immune Response Following Multivalent Dengue Vaccination and Implications for Protection Against Dengue Challenge.

A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein